Similar Search Results

Torasemide: A Pharmacoeconomic Review of its Use in Chronic Heart Failure

Young, Melissa; Plosker, Greg L. - In: PharmacoEconomics 19 (2001) 6, pp. 679-703

double-blind comparative studies against furosemide. Torasemide has been shown to be at least as effective as furosemide in … receiving torasemide had significantly reduced hospital admission rates compared with patients receiving furosemide … $US1944.76 to $US470.76 PPPM) of torasemide treatment. In the furosemide group, average monthly costs for patients …

Persistent link: https://www.econbiz.de/10005590529

Cost Estimates for Chronic Diseases

Woo, Jean; Cockram, Clive - In: Disease Management and Health Outcomes 8 (2000) 1, pp. 29-41

With increasing chronic disease and disability burden as a result of the aging of populations worldwide, cost estimates of disease and disability are important in determining: 1. the most cost-effective methods in delivering healthcare in order to maximise resources; and 2. health policies and...

Persistent link: https://www.econbiz.de/10005448788

Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies

Levy, Emile; Levy, Pierre - In: PharmacoEconomics 20 (2002) 14, pp. 963-977

Over the last two decades the incidence of congestive heart failure (CHF) has increased with aging of the population and in spite of the decline in age-adjusted mortality rates due to coronary heart disease. Its management has seen substantial progress, embodied in the introduction of ACE...

Persistent link: https://www.econbiz.de/10005448970

Specialist Nurse Management Programmes: Economic Benefits in the Management of Heart Failure

Stewart, Simon; Horowitz, John D. - In: PharmacoEconomics 21 (2003) 4, pp. 225-240

Chronic heart failure (CHF) is a modern-day epidemic in most developed countries. As such, it is both common and costly. Contrary to the impression given by clinical trial data, CHF mainly affects older individuals with approximately equal numbers of men and women and concurrent disease profiles...

Persistent link: https://www.econbiz.de/10005449073

Standardized Telephonic Case Management in a Hispanic Heart Failure Population: An Effective Intervention

Riegel, Barbara; Carlson, Beverly; Glaser, Dale; Kopp, Zoe - In: Disease Management and Health Outcomes 10 (2002) 4, pp. 241-249

Background: Heart failure (HF) is as common in Hispanic as it is in non-Hispanic populations. However, there do not appear to be any published reports of HF disease management programs which include Hispanic populations. Objective: To test the effectiveness of a standardized telephonic disease...

Persistent link: https://www.econbiz.de/10005404647

Analysis of Asthma-Related Costs and Patterns of Resource Utilization in a Managed-Care Population

Armstrong, Edward P.; Krueger, Kem; Langley, Paul C. - In: Disease Management and Health Outcomes 9 (2001) 3, pp. 161-171

Objectives: To identify the asthma prevalence rate, the total healthcare and asthma-related treatment costs, and the medical and pharmacy costs associated with different asthma medication usage patterns in a managed-care organisation (MCO). Study design and participants: The medical and pharmacy...

Persistent link: https://www.econbiz.de/10005590104

Excess Healthcare Costs Associated with Excess Health Risks in Diseased and Non-Diseased Health Risk Appraisal Participants

Musich, Shirley; McDonald, Timothy; Hirschland, David; … - In: Disease Management and Health Outcomes 10 (2002) 4, pp. 251-258

Background: Concerns regarding the effectiveness and impact of disease management are largely based on disease compliance measures. Although disease management programs have measured improvements in compliance and quality of life and cost savings from reductions in hospitalizations and emergency...

Persistent link: https://www.econbiz.de/10005590126

Risperidone, Haloperidol and Clozapine in the South Carolina Medicaid Program: A Comparative Analysis of Utilisation and Expenditure

Shermock, Kenneth M.; Sadik, M. Kay; Kozma, Chris M.; … - In: Disease Management and Health Outcomes 9 (2001) 4, pp. 203-213

Objective: To determine whether the increased acquisition costs associated with the atypical antipsychotic risperidone are offset by reductions in other mental health care utilisation and expenditure. Design and setting: The study was population-based and used South Carolina Medicaid claims data...

Persistent link: https://www.econbiz.de/10005590139

Cost and Cost Effectiveness of Venous and Pressure Ulcer Protocols of Care

Kerstein, Morris D.; Gemmen, Eric; van Rijswijk, Lia; … - In: Disease Management and Health Outcomes 9 (2001) 11, pp. 651-636

Background: To meet the challenge of an aging population, providers and payors must optimize chronic wound care outcomes and contain costs. Objective: To explore the costs, outcomes, and effects of outcomes on costs of pressure and venous ulcer woundcare protocols. Design: Modeling study using...

Persistent link: https://www.econbiz.de/10005590178

Spotlight on Galantamine in Alzheimer's Disease This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in PharmacoEconomic...

Lyseng-Williamson, Katherine A.; Plosker, Greg L. - In: Disease Management and Health Outcomes 11 (2003) 2, pp. 125-128

Galantamine is one of several orally administered cholinesterase inhibitors that improve cognition in patients with mild to moderate Alzheimer's disease. Compared with placebo, galantamine 16 or 24 mg/day improved cognition and activities of daily living, delayed emergence of behavioral symptoms...

Persistent link: https://www.econbiz.de/10005590191

1
2
3
4
5
6
7
8
9
10
Next
Last